The UT SPORE Career Development Program has the following objectives:1. Establish a Structure for the SPORE Career Development Research Program. Publicize theavailability of start-up funding for pilot projects in lung cancer translational research. Develop a peerreviewmechanism to select competing proposals for funding using internal and external reviewers.Develop specific criteria for selection of projects for funding for use by the reviewers. The SPOREAdministrative Core plays a major role in this.2. Project Identification. Identify projects that are innovative and have significant potential for reducinglung cancer incidence, morbidity, and deaths. The expertise of SPORE Pis, Project Leaders, Coinvestigators,and the scientific advisory board will be sought to achieve this goal.3. SPORE Collaborations. Encourage collaborations among scientists in the SPORE and with scientistsoutside the SPORE environment that will help investigators reach their objectives. Teach investigatorsabout lung cancer and the current important scientific and clinical questions. Put investigators in contactwith other lung cancer researchers at UTSW and MDACC and at other SPORE institutions.4. Help Investigators to Define Their Career Development Project. Have the SPORE PI and Co-Piwork with investigators to define and articulate translational research goals and steps required tobeneficially translate the research into application in humans. Help the investigators to 'crystallize' theproblem, show them the unique resources available to help answer the problem (e.g. SPOREPathology and Tissue Resource), help them develop an appropriate statistical design for their project atan early stage (with the assistance of SPORE Biostatistics Core C).5. Career Development Project Funding. Provide development funding (usually in the amount of-$25,000) for projects in The University of Texas SPORE and for scientists at other institutions outsidethe SPORE environment.6. Provide a Mechanism for Followup, Quality Control, Use of SPORE Resources, and Mentorshipfor Career Development Awardees. Develop a mechanism for the SPORE PI and Co-Pi to closelymonitor and work with the Career Development Awardees to help achieve their translational researchgoals. Encourage Developmental Project investigators to use the SPORE Bioinformatics andBiostatistics Cores C and D in the collection, storage, and analysis of their data. Insist on presentationof 'works in progress' reports at the regular joint SPORE UTSW7MDACC videoconferences as well asannual written reports. Provide mentors expert in lung cancer translational research for the CareerDevelopment Projects. Review and help Career Development Project Investigators prepare their resultsfor presentation and encourage presentation at inter SPORE related meetings such as at the annualSPORE meeting and lung cancer specific inter SPORE meetings.7. Provide Help With Obtaining Other Peer Reviewed Funding. Encourage preparation of other peerreviewed funding applications, identify funding sources for lung cancer work, help with grant draftreview, and provide letters of support for these applications.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
2P50CA070907-11
Application #
7507403
Study Section
Special Emphasis Panel (ZCA1-GRB-I (M1))
Project Start
2008-09-01
Project End
2013-04-30
Budget Start
2008-09-01
Budget End
2009-04-30
Support Year
11
Fiscal Year
2008
Total Cost
$58,603
Indirect Cost
Name
University of Texas Sw Medical Center Dallas
Department
Type
DUNS #
800771545
City
Dallas
State
TX
Country
United States
Zip Code
75390
Mender, Ilgen; LaRanger, Ryan; Luitel, Krishna et al. (2018) Telomerase-Mediated Strategy for Overcoming Non-Small Cell Lung Cancer Targeted Therapy and Chemotherapy Resistance. Neoplasia 20:826-837
Gong, Ke; Guo, Gao; Gerber, David E et al. (2018) TNF-driven adaptive response mediates resistance to EGFR inhibition in lung cancer. J Clin Invest 128:2500-2518
Wang, Jacqueline F; Pu, Xingxiang; Zhang, Xiaoshan et al. (2018) Variants with a low allele frequency detected in genomic DNA affect the accuracy of mutation detection in cell-free DNA by next-generation sequencing. Cancer 124:1061-1069
Rashdan, Sawsan; Minna, John D; Gerber, David E (2018) Diagnosis and management of pulmonary toxicity associated with cancer immunotherapy. Lancet Respir Med 6:472-478
Pierzynski, Jeanne A; Ye, Yuanqing; Lippman, Scott M et al. (2018) Socio-demographic, Clinical, and Genetic Determinants of Quality of Life in Lung Cancer Patients. Sci Rep 8:10640
Akbay, Esra A; Kim, James (2018) Autochthonous murine models for the study of smoker and never-smoker associated lung cancers. Transl Lung Cancer Res 7:464-486
Zhang, Wei; Girard, Luc; Zhang, Yu-An et al. (2018) Small cell lung cancer tumors and preclinical models display heterogeneity of neuroendocrine phenotypes. Transl Lung Cancer Res 7:32-49
Tan, Xiaochao; Banerjee, Priyam; Liu, Xin et al. (2018) The epithelial-to-mesenchymal transition activator ZEB1 initiates a prometastatic competing endogenous RNA network. J Clin Invest 128:1267-1282
McMillan, Elizabeth A; Ryu, Myung-Jeom; Diep, Caroline H et al. (2018) Chemistry-First Approach for Nomination of Personalized Treatment in Lung Cancer. Cell 173:864-878.e29
Walser, Tonya C; Jing, Zhe; Tran, Linh M et al. (2018) Silencing the Snail-Dependent RNA Splice Regulator ESRP1 Drives Malignant Transformation of Human Pulmonary Epithelial Cells. Cancer Res 78:1986-1999

Showing the most recent 10 out of 1059 publications